Our top pick for
Building a portfolio
Biodesix, Inc is a diagnostics & research business based in the US. Biodesix shares (BDSX) are listed on the NASDAQ and all prices are listed in US Dollars. Biodesix employs 200 staff and has a trailing 12-month revenue of around USD$45.6 million.
|52-week range||USD$10.85 - USD$31.99|
|50-day moving average||USD$19.9294|
|200-day moving average||USD$19.4658|
|Wall St. target price||USD$28|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$45.6 million|
|Gross profit TTM||USD$23.6 million|
|Return on assets TTM||-16.64%|
|Return on equity TTM||-627.88%|
|Market capitalisation||USD$503.9 million|
TTM: trailing 12 months
There are currently 390,212 Biodesix shares held short by investors – that's known as Biodesix's "short interest". This figure is 2.9% down from 401,775 last month.
There are a few different ways that this level of interest in shorting Biodesix shares can be evaluated.
Biodesix's "short interest ratio" (SIR) is the quantity of Biodesix shares currently shorted divided by the average quantity of Biodesix shares traded daily (recently around 103779.78723404). Biodesix's SIR currently stands at 3.76. In other words for every 100,000 Biodesix shares traded daily on the market, roughly 3760 shares are currently held short.
To gain some more context, you can compare Biodesix's short interest ratio against those of similar companies.
However Biodesix's short interest can also be evaluated against the total number of Biodesix shares, or, against the total number of tradable Biodesix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biodesix's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Biodesix shares in existence, roughly 10 shares are currently held short) or 0.0356% of the tradable shares (for every 100,000 tradable Biodesix shares, roughly 36 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biodesix.
Find out more about how you can short Biodesix stock.
We're not expecting Biodesix to pay a dividend over the next 12 months.
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.